BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver vaccines....
BioCentury | Sep 10, 2012
Clinical News

Voraxaze glucarpidase regulatory update

The Centers for Medicare & Medicaid Services (CMS) will provide hospitals with additional reimbursement payments beyond the predetermined standard rates for the use of BTG's Voraxaze glucarpidase to treat patients with toxic levels of methotrexate...
BioCentury | Aug 20, 2012
Regulation

(Part) A for effort

BTG plc and Optimer Pharmaceuticals Inc. are the first drug developers in a decade to take advantage of a program whereby the U.S. Centers for Medicare & Medicaid Services provides hospitals additional reimbursement to treat...
BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Carboxypeptidase B2 (CPB2; TAFI); complement 5a (C5a) Mouse and human studies suggest the enzyme CPB2 could help treat RA. In...
BioCentury | Feb 24, 2011
Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers N-terminal truncated carboxypeptidase E (CPE) as a metastasis biomarker In vitro mouse and patient sample studies suggest that truncated CPE could be...
BioCentury | Oct 1, 2009
Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Carboxypeptidase E (CPE) A study in mice suggests that increasing CPE activity in the hypothalamus could help treat obesity. In mice, animals with...
BioCentury | Sep 10, 2007
Company News

Eden Biodesign, Cancer Research UK deal

CB1954, which is off patent, is in Phase I testing with NAD(P)H dehydrogenase (quinine 2, NQO2 ) to treat hepatic cell carcinoma (HCC). Cancer Research is conducting that trial for Protherics plc (LSE:PTI; PTIL, London, U.K.)....
BioCentury | Apr 30, 2007
Clinical News

AZD9684: Development discontinued

AZN said it discontinued development of AZD9684 due to lack of efficacy in Phase II testing. AstraZeneca plc (LSE:AZN; AZN), London, U.K. Product: AZD9684 Business: Cardiovascular Molecular target: NA Description: Carboxypeptidase U (CPU) inhibitor Indication:...
BioCentury | Nov 6, 2006
Company News

MediciNova, Meiji Seika Kaisha deal

Meiji granted MediciNova a worldwide license to develop and commercialize MN-447 and MN-462. The antithrombotic compounds are in preclinical development for cardiovascular disease. The license excludes Japan and certain Asian countries. MN-447 is a cardioprotective...
BioCentury | Nov 2, 2006
Company News

Meiji licenses compounds to MediciNova, Cerexa

Meiji Seika Kaisha (Tokyo, Japan) was active on Wednesday, striking separate deals in which it granted MediciNova (Osaka:4875) and Cerexa (Alameda, Calif.) licenses for preclinical cardiovascular and infectious disease compounds, respectively. MediciNova received a worldwide...
Items per page:
1 - 10 of 30